Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2003

View Archived Issues

Safety and efficacy of bimosiamose in psoriasis

Efficacy of IDEC-114 in moderate to severe psoriasis does not reach statistical significance

Schering AG presents new estrogenic agents for contraception and cancer therapy

New PPAR modulators discovered by Novo Nordisk researchers

Novel KDR/Tie-2 inhibitors prepared and tested at Aventis

Indian team discovers new PPAR agonists with utility in diabetes, dyslipidemia, etc.

Dual NO donors/free radical scavengers under study at Merck KGaA

New orexin-1 antagonists and their use described in GSK patent

17Beta-HSD-3 inhibitors in early development at Schering-Plough

Thrombin receptor antagonists claimed by Schering-Plough

5-HT2C receptor ligands and their use in anxiety, obesity, depression, etc.

Stressgen presents preclinical data on CoVal fusion peptide targeting HBV

Preliminary phase II Onyvax-P results

Evidence of cytotoxic effects of IL-13-PE38QQR in brain cancer

Preclinical data support use of human neural stem cells in repairing nervous system

Medarex and Amrad to develop therapeutic antibodies

Teva and Eisai to codevelop rasagiline for Alzheimer's, copromote in U.S.

FDA committee recommends Valtrex for reduction of genital herpes transmission

Genmab completes phase IIb recruitment for HuMax-CD4 in psoriasis

ChemGenex completes enrollment in first part of Quinamed phase I/II trial

Evotec and Artesian enter CHF drug discovery agreement

Q1 progress at Titan

Aldurazyme launched for MPS I

RiboTargets merged into British Biotech

DOV-21947 enters clinical testing

Potent and selective inhibitor of LFA-1/ICAM-1 interaction for T-cell-dependent skin diseases

Phenolic-based topical antiinflammatory agent in development at Cutanix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...